Company Description
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.
Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment.
The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization.
Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment.
The company was founded in 2015 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 10, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Mathai Mammen |
Contact Details
Address: 30 Acorn Park Drive Cambridge, Massachusetts 02140 United States | |
| Phone | (617) 945-9510 |
| Website | parabilismed.com |
Stock Details
| Ticker Symbol | PBLS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 1657677 |
| CUSIP Number | 698955101 |
| ISIN Number | US6989551014 |
| Employer ID | 47-4505725 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mathai Mammen M.D., Ph.D. | Chief Executive Officer, President, Treasurer and Chairman |
| Teresa L. Jurgensen J.D. | Executive Vice President, Secretary and General Counsel |
| Dr. Mohammed Fawzi Benzaghou M.D. | Chief Medical Officer |
| John McGee Ph.D. | Scientific Co-Founder, Executive Vice President and Head of Platform |
| Thomas Rodolpho Kotarakos | Chief Financial Officer |
| Dr. Rohin Mhatre Ph.D. | Chief Technical Operations Officer |
| Kristen Stants | Chief People Officer |
| Dr. Jonathan Hurov Ph.D. | Executive Vice President of Discovery Biology |
| Marie Nguyen M.D. | Senior Vice President and Head of Clinical Development |
| Dr. Markus Haeberlein MSc, Ph.D. | Executive Vice President of Discovery Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 6, 2026 | SCHEDULE 13G | Filing |
| Jun 18, 2026 | SCHEDULE 13D | Filing |
| Jun 11, 2026 | 8-K | Current Report |
| Jun 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 10, 2026 | 424B4 | Prospectus |
| Jun 10, 2026 | FWP | Free Writing Prospectus |
| Jun 9, 2026 | EFFECT | Notice of Effectiveness |